JP2010120964A5 - - Google Patents

Download PDF

Info

Publication number
JP2010120964A5
JP2010120964A5 JP2010036052A JP2010036052A JP2010120964A5 JP 2010120964 A5 JP2010120964 A5 JP 2010120964A5 JP 2010036052 A JP2010036052 A JP 2010036052A JP 2010036052 A JP2010036052 A JP 2010036052A JP 2010120964 A5 JP2010120964 A5 JP 2010120964A5
Authority
JP
Japan
Prior art keywords
preparation
growth factor
methylideneaminooxy
dihydronaphthalen
biodegradation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010036052A
Other languages
English (en)
Japanese (ja)
Other versions
JP5287761B2 (ja
JP2010120964A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2010036052A priority Critical patent/JP5287761B2/ja
Priority claimed from JP2010036052A external-priority patent/JP5287761B2/ja
Publication of JP2010120964A publication Critical patent/JP2010120964A/ja
Publication of JP2010120964A5 publication Critical patent/JP2010120964A5/ja
Application granted granted Critical
Publication of JP5287761B2 publication Critical patent/JP5287761B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010036052A 2002-10-10 2010-02-22 内因性修復因子産生促進剤 Expired - Fee Related JP5287761B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010036052A JP5287761B2 (ja) 2002-10-10 2010-02-22 内因性修復因子産生促進剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2002298079 2002-10-10
JP2002298079 2002-10-10
JP2002318830 2002-10-31
JP2002318830 2002-10-31
JP2003117604 2003-04-22
JP2003117604 2003-04-22
JP2010036052A JP5287761B2 (ja) 2002-10-10 2010-02-22 内因性修復因子産生促進剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005501023A Division JP4497320B2 (ja) 2002-10-10 2003-10-09 内因性修復因子産生促進剤

Publications (3)

Publication Number Publication Date
JP2010120964A JP2010120964A (ja) 2010-06-03
JP2010120964A5 true JP2010120964A5 (enExample) 2010-07-15
JP5287761B2 JP5287761B2 (ja) 2013-09-11

Family

ID=32096713

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005501023A Expired - Fee Related JP4497320B2 (ja) 2002-10-10 2003-10-09 内因性修復因子産生促進剤
JP2010036052A Expired - Fee Related JP5287761B2 (ja) 2002-10-10 2010-02-22 内因性修復因子産生促進剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2005501023A Expired - Fee Related JP4497320B2 (ja) 2002-10-10 2003-10-09 内因性修復因子産生促進剤

Country Status (10)

Country Link
US (3) US7547715B2 (enExample)
EP (2) EP1563846B1 (enExample)
JP (2) JP4497320B2 (enExample)
AU (1) AU2003272963A1 (enExample)
DK (2) DK2465537T3 (enExample)
ES (2) ES2584606T3 (enExample)
HU (1) HUE029417T2 (enExample)
PT (2) PT2465537T (enExample)
TW (1) TW200413000A (enExample)
WO (1) WO2004032965A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032965A1 (ja) 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
WO2005072743A1 (ja) * 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
JP4775663B2 (ja) * 2005-03-30 2011-09-21 地方独立行政法人 大阪府立病院機構 血管新生制御方法
US9422521B2 (en) * 2005-09-12 2016-08-23 Es Cell International Pte Ltd. Differentiation of pluripotent stem cells with a kinase inhibitor or PGI2
WO2007061889A2 (en) 2005-11-17 2007-05-31 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix
ES2427993T3 (es) 2006-02-09 2013-11-05 Biomimetic Therapeutics, Llc Composiciones y métodos para el tratamiento de hueso
CN101495623B (zh) 2006-03-24 2013-09-11 儿童医疗中心有限公司 调节造血干细胞生长的方法
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
WO2008005427A2 (en) 2006-06-30 2008-01-10 Biomimetic Therapeutics, Inc. Pdgf-biomatrix compositions and methods for treating rotator cuff injuries
US20080171972A1 (en) * 2006-10-06 2008-07-17 Stopek Joshua B Medical device package
ES2459743T3 (es) * 2006-10-19 2014-05-12 Ono Pharmaceutical Co., Ltd. Preparación de liberación sostenida para terapia de regeneración tisular
EP2679221B1 (en) 2006-10-20 2020-09-23 Children's Medical Center Corporation Method to enhance tissue regeneration
AU2013213727B2 (en) * 2006-10-20 2016-03-17 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2085088A4 (en) * 2006-10-26 2012-08-29 Ono Pharmaceutical Co ADHESIVE PREPARATION
EP2462895B1 (en) 2006-11-03 2016-11-02 BioMimetic Therapeutics, LLC Compositions and methods for arthrodetic procedures
WO2008058766A1 (en) * 2006-11-16 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
JP2008195660A (ja) * 2007-02-14 2008-08-28 Kitasato Institute 中枢循環改善薬
CA2715254A1 (en) 2008-02-07 2009-08-13 Biomimetic Therapeutics, Inc. Compositions and methods for distraction osteogenesis
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
ES2557303T3 (es) * 2008-06-23 2016-01-25 Nippon Shinyaku Co., Ltd. Agente terapéutico para la estenosis del canal espinal
CN102231992B (zh) 2008-09-09 2015-05-20 生物模拟治疗公司 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US20100267826A1 (en) * 2009-04-20 2010-10-21 The Board Of Trustees Of The Leland Stanford Junior University Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists
US20100305203A1 (en) * 2009-05-27 2010-12-02 Sucampo Ag Method for modulating claudin mediated functions
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
EP3167875A1 (en) * 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
BR112012020566B1 (pt) 2010-02-22 2021-09-21 Biomimetic Therapeutics, Llc Composição de fator de crescimento derivado de plaqueta
MX2013001227A (es) * 2010-07-30 2013-04-24 Allergan Inc Compuestos y metodos para reparacion de piel.
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
BR112013021035A2 (pt) * 2011-02-17 2016-10-11 Allergan Inc composições e métodos de reposição de tecido macio aperfeiçoados
EP2678022A2 (en) * 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
ES2665569T3 (es) 2011-03-01 2018-04-26 Pharnext Tratamiento de la isquemia cerebral
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
WO2013082243A1 (en) 2011-12-02 2013-06-06 Fate Therapeutics, Inc. Enhanced stem cell composition
JP6106688B2 (ja) 2011-12-02 2017-04-05 フェイト セラピューティクス，インコーポレイテッド 虚血を処置する改善された方法
WO2014046065A1 (ja) 2012-09-21 2014-03-27 国立大学法人大阪大学 心筋・血管再生デバイスとしての重症心不全治療材
JP6400479B2 (ja) * 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
CA2890034A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
JP6449166B2 (ja) * 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9763911B2 (en) * 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
JPWO2018124236A1 (ja) 2016-12-27 2019-11-14 国立大学法人大阪大学 難治性心疾患治療用医薬組成物
WO2018227134A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
WO2019023579A1 (en) * 2017-07-27 2019-01-31 The Mclean Hospital Corporation METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF PATHOLOGIES MEDIATED BY NURR1 AND PPARY
US20210113464A1 (en) * 2017-11-27 2021-04-22 Osaka University Disease-site-specific liposomal formulation
JP7233087B2 (ja) * 2019-03-18 2023-03-06 公立大学法人横浜市立大学 抗動脈硬化剤
CA3155464A1 (en) 2019-10-28 2021-05-06 Mark Williams Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives
CA3167058A1 (en) 2020-02-12 2021-08-19 Cytoagents, Inc. Compositions and methods for treating coronavirus infections
EP4126054A4 (en) * 2020-03-31 2024-05-15 Ensysce Biosciences, Inc. METHOD OF TREATING VIRUS INFECTIONS WITH NAFAMOSTAT
KR20220040169A (ko) * 2020-09-23 2022-03-30 (주)아이엠디팜 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 포함하는 경구투여용 제제
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (enExample) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
JPS503362B1 (enExample) 1970-06-10 1975-02-04
JPS5231404B1 (enExample) 1971-04-28 1977-08-15
US3965143A (en) 1974-03-26 1976-06-22 G. D. Searle & Co. 16-Oxygenated prostanoic acid derivatives
US4132738A (en) 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
DE2912409A1 (de) 1978-03-31 1979-10-11 Ono Pharmaceutical Co 6,9-methano-pgi tief 2 -analoge
JPS54130543A (en) 1978-03-31 1979-10-09 Ono Pharmaceut Co Ltd Prostagladin i2 analog, and its preparation
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
US4650804A (en) 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
JPS6130519A (ja) 1984-07-23 1986-02-12 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患治療剤
JPS62134787A (ja) 1985-12-06 1987-06-17 株式会社クボタ 自動販売機の商品払出し装置
KR100191137B1 (ko) * 1992-07-21 1999-06-15 사노 가즈오 옥심 유도체
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
JP3162668B2 (ja) 1997-02-04 2001-05-08 小野薬品工業株式会社 ω−シクロアルキル−プロスタグランジンＥ２誘導体
PT1008588E (pt) 1997-02-10 2003-09-30 Ono Pharmaceutical Co Derivados da 11,15-o-diaklquil-prostaglandina e processo de producao dos mesmos e farmaco que os contem como ingrediente activo
WO1998058911A2 (en) 1997-06-23 1998-12-30 Pfizer Inc. Prostaglandin agonists
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
EP1008349A4 (en) 1997-08-27 2004-01-14 Mitsubishi Pharma Corp PROMOTORS OF NEOVASCULARIZATION
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US5877211A (en) 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
WO1999033794A1 (en) 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES
WO1999043736A1 (en) 1998-02-27 1999-09-02 Ono Pharmaceutical Co., Ltd. Carrier polymers migrating into target organs and drug-containing polymers
JP4123568B2 (ja) 1998-05-06 2008-07-23 小野薬品工業株式会社 ６−オキソ−ｐｇｅ１化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンｅ２受容体作働薬
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
JP2000086517A (ja) * 1998-09-16 2000-03-28 Ono Pharmaceut Co Ltd アロディニア治療剤
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
JP2002527400A (ja) 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨形成刺激方法
JP2000239188A (ja) 1998-12-22 2000-09-05 Mitsubishi Chemicals Corp 育毛剤
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
AU2183800A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of dry eye
WO2000038667A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
SE9900025D0 (sv) 1999-01-08 1999-01-08 Synphora Ab Method and composition for treatment of female sexual dysfunction
CA2332375A1 (en) 1999-03-16 2000-09-21 Masafumi Isogaya Cervical ripening agent and cervical ripening method
EP1080728A1 (en) 1999-03-16 2001-03-07 Toray Industries, Inc. Prostaglandin ep4 receptor agonist and treatment method
ES2274378T3 (es) 1999-08-10 2007-05-16 Glaxo Group Limited Ligando del receptor ep4 y uso contra dolor neuropatico, cancer de colon,hiv y migraña.
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
WO2001046140A1 (en) 1999-12-22 2001-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2001072268A1 (en) * 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
FR2812190B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
US6376533B1 (en) 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US20020161026A1 (en) 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
SI1339678T1 (sl) 2000-11-27 2007-12-31 Pfizer Prod Inc Selektivni agonisti EP4 receptorja pri zdravljenju osteoporoze
GB0030541D0 (en) 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
US7410991B2 (en) 2001-10-23 2008-08-12 Laboratoires Serono S.A. Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
US7335680B2 (en) 2001-12-20 2008-02-26 Laboratoires Serono Sa Pyrrolidine derivatives as prostaglandin modulators
WO2004032965A1 (ja) * 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
ES2459743T3 (es) 2006-10-19 2014-05-12 Ono Pharmaceutical Co., Ltd. Preparación de liberación sostenida para terapia de regeneración tisular

Similar Documents

Publication Publication Date Title
JP2010120964A5 (enExample)
JP2011201907A5 (enExample)
JP2011037901A5 (enExample)
JP2017513836A5 (enExample)
JP2012255026A5 (enExample)
JP2011528658A5 (enExample)
JP2010077141A5 (enExample)
JP2007302683A5 (enExample)
JP2012533546A5 (enExample)
JP2014515013A5 (enExample)
JP2009523760A5 (enExample)
JP2013542247A5 (enExample)
JP2008528441A5 (enExample)
JP2014521744A5 (enExample)
JP2013520405A5 (enExample)
JP2016511753A5 (enExample)
WO2014093579A3 (en) Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt
JP2017505285A5 (enExample)
JP2009537554A5 (enExample)
JP2013529637A5 (enExample)
JP2012512164A5 (enExample)
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
WO2011129579A3 (en) Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent
WO2013128419A3 (en) Pharmaceutical compositions comprising boronic acid compounds
TR201906158T4 (tr) Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar.